CGTN
17.9.2020 12:03:22 CEST | Business Wire | Press release
China has vowed to eradicate absolute poverty in rural areas by the end of 2020 despite the COVID-19 epidemic. While efforts are being made to ensure "no single poor area or individual shall be left behind" – as President Xi Jinping puts it – people that have recently shaken off poverty are striving for a better life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005399/en/
Among the 529 residents in a small village in central China's Hunan Province, 95 in 30 households used to live under the poverty line. The whole village was lifted out of poverty through rural tourism in 2018, and the average annual income of the residents reached 13,840 yuan (about 2,060 U.S. dollars) last year – way above the national poverty line of 2,300 yuan (about 340 U.S. dollars).
Shazhou Village, located in a mountainous area in Rucheng County, Chenzhou City, was the first stop of Xi's inspection tour in Hunan.
Xi, also general secretary of the Communist Party of China (CPC) Central Committee, visited the village on Wednesday and learned about poverty relief industries and progress in consolidating poverty eradication at a modern agricultural tourism demonstration base.
Targeted poverty alleviation
China has adopted a targeted approach in its poverty alleviation campaign, which means taking tailored relief measures to fit different local conditions.
The story of Shazhou is a prime example of that approach. The village boasts the beautiful scenery of the Luoxiao Mountains and the unique Yao ethnic culture – nearly two thirds of the residents belong to the Yao ethnic group. Tourism has played a significant role in Shazhou's battle against poverty.
The village has promoted rural tourism and high-quality fruit planting, and arranged training programs to help villagers obtain such job skills as for restaurant cooks and rural tourism industry employees. More than 350 local jobs have been created through the efforts.
With all its residents lifted out of poverty, Shazhou has also been known for such national-level honor as the "village of beauty and leisure," "role model for ethnic unity and progress," "key village for promoting rural tourism" and "traditional Chinese village."
New starting point
Since the 18th CPC National Congress in late 2012, China has achieved remarkable results in poverty reduction. More than 93 million rural people shook off poverty between 2013 and 2019.
But 5.51 million people needed to get rid of poverty by the end of 2019. And such a formidable task was coincided by accident with the coronavirus outbreak.
Speaking at a symposium on poverty alleviation in March, Xi described the goal of ending absolute poverty by 2020 as a "solemn pledge" made by the CPC Central Committee to the Chinese people, urging authorities at all levels to deliver on that promise.
As China intensifies efforts in the final stage of the tough battle, Xi tours around the country to inspect economic and social development, with poverty alleviation high on the agenda. Prior to the Hunan trip, he had taken inspection tours this year of capital city Beijing and provinces of Yunnan, Hubei, Zhejiang, Shaanxi, Shanxi, Jilin and Anhui, and Ningxia Hui Autonomous Region.
In addition to increasing poor people's incomes, China is also striving to improve the quality of poverty relief. Xi has repeatedly called for efforts to ensure rural poor people do not have to worry about food and clothing and have access to compulsory education, basic medical services and safe housing.
Meanwhile, he is looking into the future beyond the end of poverty. "Being lifted out of poverty is not an end in itself but the starting point of a new life and a new pursuit," he said on several occasions this year, calling for consolidating achievements in poverty alleviation and advancing the rural vitalization strategy.
Put forward at the 19th CPC National Congress in 2017, the strategy aims to build rural areas with thriving businesses, pleasant living environments, social etiquette and civility, effective governance and prosperity.
Shazhou is among many previously poor villages in China that have embarked on the journey for a better future.
On Wednesday, Xi also visited a revolution-themed exhibition hall, a village service center, a clinic, a primary school and the homes of villagers in Shazhou.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005399/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
